Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 5NET 3Gastrointestinal 2

Conditions

Neuroendocrine Tumors 4Gastro-enteropancreatic neuroendocrine tumor 4Carcinoma, Hepatocellular 2Carcinoid Tumor 2Pancreatic Neoplasms 1Neoplastic Cells, Circulating 1Gastrointestinal Neoplasms 1Adenoma, Islet Cell 1Acromegaly 1

Interventions

lanreotide 2Temozolomide 2Capecitabine 2zimberelimab 1veliparib 1pembrolizumab 1ganitumab 1conatumumab 1arginyllysine 1Sunitinib 1Rose Bengal 1Quality of Life 1Patient Reported Outcome Measures 1Octreotide 1Molecular Diagnostic Techniques 1Immunotherapy 1Everolimus 1Drug Therapy 1Biological Therapy 1Bevacizumab 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoid Tumor × lanreotide × Gastrointestinal × Clear all
NCT05477576 2026-03-30

ACTION-1

RayzeBio, Inc.

Phase 3 Recruiting
338 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT02859064 2023-12-05

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

SCRI Development Innovations, LLC

Phase 2 Terminated
6 enrolled 12 charts
EndocrineGastrointestinalNET

Carcinoid Tumor, Gastrointestinal Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡